
Today's most important upgrades
By Davit Kirakosyan Etsy (NASDAQ:ETSY) shares rose more than 4% intra-day today after Needham & Company upgraded the company to Buy from Hold with a price target of $160.00, noting that...
By Davit Kirakosyan Etsy (NASDAQ:ETSY) shares rose more than 4% intra-day today after Needham & Company upgraded the company to Buy from Hold with a price target of $160.00, noting that...
By Senad Karaahmetovic Bank of America analysts downgraded Pfizer (NYSE:PFE) stock to Neutral from Buy, citing long-term uncertainty. The analysts flag two key concerns: 1) the magnitude...
PDS Biotechnology Corporation (NASDAQ: PDSB) announced an exclusive global license agreement with Merck KGaA (OTC: MKGAF) (OTC: MKKGY) for the tumor-targeting IL-12 fusion protein M9241...
By Daniel Shvartsman Investing.com -- Entering the last trading day of the year, it's no surprise to find the 2022 scoreboard filled with energy winners and tech losers.The Dow Jones...
Beijing's decision to authorize the drug, its second developed abroad after Pfizer's Paxlovid, comes amid domestic shortages of everything from fever-reducing medicines to antivirals that...
China's health service approved an antiviral to treat COVID-19 as one health company estimates the country will see a doubling of its current wave of cases.
China approves Merck antiviral as it battles COVID-19 wave
Mersana Therapeutics Inc (NASDAQ: MRSN) signed a deal for developing antibody-drug conjugates (ADCs) for cancer treatment with Germany's Merck KGaA (OTC: MKGAF) (OTC: MKKGY). Mersana would...
According to a large study, dubbed PANORAMIC, Merck & Co Inc's (NYSE: MRK) COVID-19 antiviral molnupiravir speeds up recovery but does not reduce the hospitalization or death rate in...
(Reuters) – Mersana Therapeutics Inc said on Thursday it had signed a deal for developing cancer drugs with Germany’s Merck KGaA that has the potential to generate up to $800 million in...
Merck & Co Inc (NYSE: MRK) and Kelun-Biotech (a holding subsidiary of Sichuan Kelun Pharmaceutical Co Ltd) have entered into an exclusive license and collaboration agreement to develop seven...
Merck & Co. Inc. said Thursday that it entered into an agreement with Sichuan Kelun Pharmaceutical Co. Ltd. to develop seven new cancer therapies. Merck will pay the Chinse biotech an...
Merck & Co Inc (NYSE: MRK) has notified NGM Biopharmaceuticals Inc (NASDAQ: NGM) that it will not exercise its option to license NGM621 and its related compounds. Merck will also not...
By Senad Karaahmetovic Morgan Stanley analysts raised the price target on Moderna (NASDAQ:MRNA) stock to $209 per share from the prior $170 after updating the model to account for the...
Ebola vaccines developed by Johnson & Johnson (NYSE: JNJ) and Merck & Co Inc (NYSE: MRK) produced virus-fighting antibodies and appeared to be safe in children and adults, two studies...
The FDA will extend the Prescription Drug User Fee Act (PDUFA) date for AstraZeneca Plc (NASDAQ: AZN) and Merck & Co Inc's (NYSE: MRK) supplemental marketing application for Lynparza...
By Davit Kirakosyan Best Buy Co Inc (NYSE:BBY) shares fell more than 3% today after BofA Securities downgraded the company to Underperform from Neutral and lowered its price target to...
By Liz Moyer Investing.com -- Stocks were rising on Wednesday as investors prepared to hear the Federal Reserve's decision on interest rates and forecasts for the economy. Here are the...
By Senad Karaahmetovic Moderna (NASDAQ:MRNA) shares surged nearly 20% yesterday after the company’s mRNA cancer vaccine, developed together with Merck & Company Inc (NYSE:MRK), met the...
Pune, Dec. 14, 2022 (GLOBE NEWSWIRE) -- According to the latest report published by Growth Plus Reports, the global microdermabrasion devices market is expected to clock US$ 1,042.4...
The benchmark S&P 500 jumped as much as 2.76% to a three-month high early in the trading session on news that November.
By Liz Moyer Investing.com -- Stocks gave back most of their early gains on Tuesday after the November inflation report showed prices cooling more than expected. Here are the midday movers...
By Sam Boughedda Moderna (NASDAQ:MRNA) and Merck (NYSE:MRK) shares rose Tuesday morning after the companies said mRNA-4157/V940, an investigational mRNA cancer vaccine, in combination...
By Julie Steenhuysen and Michael Erman CHICAGO (Reuters) -A combination of Moderna Inc’s experimental melanoma vaccine and Merck & Co’s blockbuster immunotherapy Keytruda cut the risk of...
Moderna Inc (NASDAQ: MRNA) and Merck & Co Inc (NYSE: MRK) announced the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial of mRNA-4157/V940 combined with Keytruda met its primary endpoint. Results...
Merck & Co. Inc. and Moderna Inc. said Tuesday that their experimental mRNA-based cancer vaccine reduced the risk of recurrence or death when used with Merck's Keytruda in patients with...
JAKARTA (Reuters) – Indonesia will produce drugmaker Merck & Co’s vaccines for human papillomavirus (HPV), the chief of its state-owned pharmaceutical company Bio Farma said on Tuesday,...
By Scott Kanowsky Investing.com -- Amgen Inc. (NASDAQ:AMGN) has agreed to buy Horizon Therapeutics PLC (NASDAQ:HZNP) in an all-cash deal that values the biotech firm at about $28.3 billion,...
By Scott Kanowsky Investing.com -- Shares in Sanofi SA (EPA:SASY) rose on Monday after the French drugmaker backed out of its plans to bid for biotech company Horizon Therapeutics PLC...
Here are the biggest fresh dividend hikes and special dividends, as first covered on InvestingPro+, including several predicted by data from Investing.com and StreetInsider last weekend. Get...
By Michael Erman (Reuters) – U.S. drugmaker Merck & Co hopes to patent a new formulation of its $20 billion cancer immunotherapy Keytruda that can be injected under the skin, allowing it...
Companies often establish a pattern of hiking dividends at the same time each year, giving investors a reliable cash influx and enticing them to stick around for the long term. With help...
Here are 6 head-turning deal dispatches from the past week, as covered first on InvestingPro+. 1. Activision Blizzard (NASDAQ:ATVI) stock slipped this week after Politico reported the U.S....
By Investing.com Staff After surging nearly 16% Tuesday on fresh takeover rumors, Mirati Therapeutics (NASDAQ:MRTX) is adding another 5% Wednesday as Wall Street analysts weigh in on the...
By Peter Nurse Investing.com -- Stocks in focus in premarket trade on Monday, November 21st. Please refresh for updates. Walt Disney (NYSE:DIS) stock soared 8.5% after the...
By Sam Boughedda Credit Suisse analysts said Friday that the firm is initiating coverage of U.S. large-cap pharmaceuticals with four Outperform ratings, two Neutral ratings, and one...
By Investing.com Staff Stocks staged an explosive rally on Thursday after the CPI report was cooler than expected, which stoked hopes the Fed will slow the pace of rate increases sooner...
By Sam Boughedda Raymond James analysts told investors in a note Thursday that Seagen Inc (NASDAQ:SGEN) announcing David Epstein as their new Chief Executive Officer and member of the board...
By Senad Karaahmetovic Merck & Company Inc (NYSE:MRK) delivered higher-than-expected top and bottom-line numbers for its third quarter, allowing it to raise its full-year guidance. Merck...
Merck (MRK) reported Q3 EPS of $1.85, $0.10 better than the analyst estimate of $1.75. Revenue for the quarter came in at $15 billion versus the consensus estimate of $14.07...
By Yasin Ebrahim Investing.com -- The Dow slipped Wednesday, as the Federal Reserve’s September minutes signaling higher for longer rates overshadowed a surge in Pepsi following...
By Senad Karaahmetovic Shares of Moderna (NASDAQ:MRNA) are up about 14% in pre-market Wednesday trading after Merck (NYSE:MRK) exercised its option to jointly develop and commercialize a...
By Davit Kirakosyan Guggenheim upgraded Merck & Company Inc (NYSE:MRK) to Buy from Neutral with a price target of $104.00. According to the analysts, the company is poised to beat 2023...
By Sam Boughedda Merck (NYSE:MRK) announced positive top-line results from the pivotal Phase 3 STELLAR trial evaluating the safety and efficacy of sotatercept on Monday. The company said...
By Scott Kanowsky Investing.com -- Stocks in focus in premarket trade on Monday, October 10th. Please refresh for updates. Rivian Automotive Inc (NASDAQ:RIVN) shares slumped after the...
By Yasin Ebrahim Investing.com -- The Dow cut some losses Thursday, but remained firmly in the red as growth sectors of the market including consumer and tech stocks floundered on fears that...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.